Last updated 13 November 2026

The Board of Directors of EMV Capital plc is responsible for the governance of the Company, being the systems and procedures by which the Company is directed and controlled. High standards of corporate governance are a key priority of the Board, and the Directors believe that they govern the Company in the best interests of the shareholders.

The Board’s view is that sound governance is an essential element of a well-run business. The Company follows the corporate governance code published by the Quoted Companies Alliance (QCA) (the “QCA Code”) published in November 2023 as the benchmark for governance matters.

The Board’s approach to corporate governance is set out below under five areas: (1) board composition; (2) directors’ roles, responsibilities and functions; (3) remuneration and performance; (4) risk and controls framework; and (5) investor relations. The Board is of the opinion that the Group complies with the QCA Code as far as practicable having regard to size, nature, and current stage of the development of the Group. The extent of compliance with the ten principles that comprise the QCA Code, together with an explanation of any areas of non-compliance, and any steps taken or intended to move towards full compliance, is set out under “Principles and Approach” below.

1. Board composition

The Board currently comprises four Directors: two independent non-executive Directors, Dr Charles Spicer (Chair) and Dr Jonathan Robinson (Senior Independent Director), and two executive Directors, Dr Ilian Iliev (Chief Executive Officer) and Edward Hooper. Anesh Patel, Group Chief Financial Officer, is not a member of the Board.

The posts of Chair and Chief Executive Officer are held by different Directors. The Board is balanced by there being an appropriate number of non-executives with at least two of the Directors at all times during the year being non-executive directors.

Nominations Committee
The Nominations Committee is chaired by Dr Charles Spicer, with Dr Jonathan Robinson and Dr Ilian Iliev as its other members.
The Committee meets at least once a year. The Nominations Committee has responsibility, as stated in its terms of reference, for identifying and nominating, for the approval of the Board, candidates to fill Group Board vacancies as and when they arise, save those appointments as Chair or Chief Executive are matters for the full Board. The Committee is responsible for all senior appointments that are made within the Group.

Further information on the skills and experience of the Directors and on Board diversity is set out under QCA Principles 6 and 7 below.

2. Directors’ roles, responsibilities and functions

The Board meets regularly throughout the year, quarterly for major milestones and KPI reviews, and more frequently for ongoing business matters and investment decisions. Arrangements are made to enable information in a form and of a quality to be supplied to Directors on a timely basis to enable them to discharge their duties. Additionally, special meetings take place, or other arrangements are made when Board decisions are required in advance of regular meetings. Certain matters are reserved for consideration by the Board (with other matters delegated to Board committees). The Board is responsible for leading and controlling the Group and in particular, setting the Group’s strategy, its investment policy and approving its budget and major items of expenditure, acquisitions and disposals. The Board has a procedure through which the Directors are able to take independent advice in the furtherance of their responsibilities. The Directors have access to the advice and services of the General Counsel and Company Secretary.

The Board has delegated certain of its functions and responsibilities to the Nominations Committee (see section 1 above), the Remuneration Committee (see section 3 below) and the Audit & Risk Committee (see section 4 below). The role of each Director, and their contribution to the Group as described in the 2025 Annual Report, is set out below.

DirectorStatusCommittee membershipContribution (as described in the 2025 Annual Report)
Dr Jonathan RobinsonIndependent Non-Executive Director and Senior Independent DirectorChair of the Audit & Risk Committee and the Remuneration Committee; member of the Nominations CommitteeEntrepreneur, public company director and active investor. Provides independent oversight of financial reporting, internal controls and executive remuneration, and strategic input on commercial matters.
Dr Charles SpicerIndependent Non-Executive ChairChair of the Nominations Committee; member of the Audit & Risk Committee and the Remuneration CommitteeExtensive experience as a public company chair in the life sciences and medtech sectors. Oversees the Group’s governance framework and supports the Board’s consideration of complex investment and related party transactions.
Dr Ilian IlievChief Executive Officer and Executive DirectorMember of the Nominations CommitteeVenture capital, technology commercialisation and corporate finance expertise. Leads the Group’s investment strategy, the integration of Martlet Capital and the advancement of the Venture Build programme, including the acquisition of the XF-73 assets.
Edward HooperExecutive Director and General Counsel–Provides legal, strategic and commercial advice and support to the Company, the Group and portfolio companies. Legal and corporate finance expertise applied to the structuring of portfolio company transactions, fundraisings and the Group’s contractual and governance arrangements.

3. Remuneration and performance

Remuneration Committee
The Remuneration committee is chaired by Dr Jonathan Robinson, with Dr Charles Spicer as its other member. The committee meets at least twice a year. The Remuneration Committee has responsibility, as stated in its terms of reference, for making recommendations to the Board on the Company’s policy for remuneration of senior executives, reviewing the performance of executive Directors and senior management and for determining, within agreed terms of reference, specific remuneration packages for each of the executive Directors and members of senior management, including pension rights, any compensation payments and the implementation and operation of executive incentive schemes. The committee administers the Company’s share option scheme and approves grants under the scheme. The Chair and the executive Directors are responsible for setting the level of non-executive remuneration.

The Board’s approach to evaluating its own performance is described under QCA Principle 8 below. Given the size and stage of development of the Company, the Board currently considers an informal internal review to be proportionate. The Company’s remuneration policy, including the structure of Executive Director remuneration and the Phantom Carried Interest scheme, is described under QCA Principle 9 below.

4. Risk and controls framework

Audit & Risk Committee
The Audit & Risk Committee is chaired by Dr Jonathan Robinson, with Dr Charles Spicer as its other member. The Audit & Risk committee has responsibility, as stated in its terms of reference, for considering all matters relating to financial controls, reporting and external audits, the scope and results of the audits, the independence and objectivity of the auditors and keeping under review the effectiveness of the Group’s internal controls and risk management. The committee monitors the scope, results and cost-effectiveness of the audit. It has unrestricted access to the Group’s auditors. In certain circumstances, it is permitted by the Board for the auditors to supply non-audit services (in the provision of tax advice, or non-specific projects where they can add value). The committee has approved and monitored the application of this policy in order to safeguard auditor objectivity and independence.

The Directors review the principal risks faced by the Group as part of the internal controls process. The Board maintains a register of risks and reviews the Group’s risk appetite regularly, and has reviewed the effectiveness of the Group’s system of internal controls during the year. Further information is set out under QCA Principle 5 below and in the Principal Risks and Uncertainties section of the 2025 Annual Report and Accounts (pages 53 – 56).

5. Investor relations

The Board attaches great importance to providing shareholders with clear and transparent information on the Group’s activities, strategy and financial position. The executive members of the Board hold regular meetings with significant shareholders, and the Board regards the AGM as a good opportunity to communicate directly with shareholders through an open question and answer session. The results of votes at AGMs are published via RNS. Contact details are listed on the Company’s website and on all announcements released via RNS, and shareholder communications, including RNS announcements, are published in the PLC section of the website. Further information is set out under QCA Principles 3 and 10 below.

Principles and Approach

The corporate governance framework which EMV Capital plc has set out, including board leadership and effectiveness, remuneration and internal control, is based upon practices which the Board believes are proportionate to the risks inherent to the size and complexity of EMV Capital’s operations. The Board has adopted the principles of the QCA Code, which is the standard deemed appropriate by independent bodies for small and mid-size quoted companies in the UK. The extent of compliance with the ten principles that comprise the QCA Code, together with an explanation of any areas of non-compliance, and any steps taken or intended to move towards full compliance are set out below:

Request Information


Emv Positive Logo Rgb X2
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.